Literature DB >> 11403541

Problems related to acid rebound and tachyphylaxis.

D Gillen1, K E McColl.   

Abstract

Rebound acid hypersecretion after taking histamine H(2)-receptor antagonists is a now well-established class phenomenon. It has been demonstrated both basally and in response to meal and gastrin-releasing peptide stimulation, but not in response to peak pentagastrin stimulation. It is present by 3 days after treatment but has resolved by 10 days. A recent study in previously asymptomatic healthy volunteers has suggested that this phenomenon may be clinically relevant. Tachyphylaxis/tolerance after the use of H(2)-receptor antagonists is also now well established. It manifests as a loss of acid inhibitory efficacy and is also a class effect. It is present within a few doses but is not progressive after 29 days. Rebound acid hypersecretion after proton pump inhibitors has been shown for both basal and maximal acid output by 14 days after treatment. It is found in Helicobacter pylori -negative, but not positive, subjects, probably owing to the influence of the enhanced oxyntic gastritis that occurs during proton pump inhibitor therapy. It is a prolonged phenomenon, lasting for at least 2 months after a 2-month treatment course. This duration is likely to reflect its development as a result of trophic effects on the oxyntic mucosa. This trophism is caused by the marked hypergastrinaemia that occurs secondary to the profound acid suppression during proton pump inhibitor treatment. The clinical relevance of this phenomenon remains at present unknown. Tachyphylaxis/tolerance has not yet been shown in several short-term studies after taking proton pump inhibitors. A recent clinical study has, however, suggested that this phenomenon may merit longer-term evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403541     DOI: 10.1053/bega.2001.0190

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  9 in total

1.  Mechanism of acid hypersecretion post curative gastrinoma resection.

Authors:  Jeremiah V Ojeaburu; Tetsuhide Ito; Pellegrino Crafa; Cesare Bordi; Robert T Jensen
Journal:  Dig Dis Sci       Date:  2010-08-20       Impact factor: 3.199

Review 2.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

3.  Acid peptic diseases: pharmacological approach to treatment.

Authors:  Alex Mejia; Walter K Kraft
Journal:  Expert Rev Clin Pharmacol       Date:  2009-05       Impact factor: 5.045

Review 4.  The safety of drugs used in acid-related disorders and functional gastrointestinal disorders.

Authors:  Neehar Parikh; Colin W Howden
Journal:  Gastroenterol Clin North Am       Date:  2010-09       Impact factor: 3.806

5.  Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD.

Authors:  Gerald Holtmann; Marc-André Bigard; Peter Malfertheiner; Roy Pounder
Journal:  Int J Clin Pharm       Date:  2011-04-07

6.  Effect of proton pump inhibition on acid, weakly acid and weakly alkaline gastro-esophageal reflux in children.

Authors:  Helena Turk; Bruno Hauser; Jernej Brecelj; Yvan Vandenplas; Rok Orel
Journal:  World J Pediatr       Date:  2013-02-07       Impact factor: 2.764

Review 7.  Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors.

Authors:  Bjarni Thjodleifsson
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis.

Authors:  Eric T Wittbrodt; Charles Baum; David A Peura
Journal:  Clin Exp Gastroenterol       Date:  2009-11-17

Review 9.  Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.

Authors:  Lingaku Lee; Irene Ramos-Alvarez; Tetsuhide Ito; Robert T Jensen
Journal:  Int J Mol Sci       Date:  2019-10-16       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.